EMENDOBIO
Live / Applied — First extension granted (statement of use) (as of 05 Nov 2025)
What this means for you
Not registered yet, but its 28 Jun 2021 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 90798006
- Mark type
- Stylized text
- Filed
- 28 Jun 2021
- Published for opposition
- 27 Dec 2022
- Attorney of record
- LAUREN GREGORY LEIPOLD
Goods and services
- Class 001 — Chemicals: Enzymes for scientific and research purposes; nucleases and nuclease panels for scientific and research purposes; nucleases and nuclease panels derived from biotechnological processes for use in scientific and research purposes; assays and reagents for use in genetic research; nucleases and nuclease panels for use in genetic research
- Class 005 — Pharmaceuticals: Enzyme preparations for medical purposes; enzymes for medical purposes; nucleases and nuclease panels for medical purposes; reagents for use in medical genetic testing; preparations for detecting genetic predispositions for medical purposes; pharmaceutical preparations for the treatment of genetic disorders; pharmaceutical preparations for the prevention of diseases or decisions caused by genetic predispositions; pharmaceutical preparations for editing of faulty genes; chemical preparations for pharmaceutical or medical purposes, namely, for editing of faulty genes; anti-cancer preparations; pharmaceutical products for the prevention and treatment of cancer; ocular pharmaceuticals; pharmaceutical preparations and substances for the treatment of genetic blood disorders
- Class 042 — Scientific and technological services: Testing, research, or development of pharmaceutical preparations for gene therapy; testing, research, selection, optimization or development of nucleases for gene targeting, gene editing, or gene therapy; DNA analysis services for scientific research purposes; genetic testing for scientific research purposes; scientific research in the field of genetics, gene editing and genetic engineering; providing medical and scientific research information in the fields of pharmaceuticals and genetics; scientific research consulting in the field of genetics; scientific research consulting in the field of gene editing; scientific research consulting in the field of selection and optimization of nucleases for gene editing and pharmaceutical development; scientific research in the field of selection and optimization of nucleases for gene editing and pharmaceutical development; pharmaceutical research services in the field of genetics and gene therapy, excluding production technologies; pharmaceutical research and development in the field of genetics and gene therapy, excluding production technologies; pharmaceutical products development in the field of genetics and gene therapy; pharmaceutical product evaluation in the field of genetics and gene therapy; pharmaceutical drug development services in the field of genetics and gene therapy, excluding production technologies; development of pharmaceutical preparations and medicines in the field of genetics and gene therapy; technical research in the field of pharmaceutical studies in the field of genetics and gene therapy, excluding production technologies; research and development in the pharmaceutical and biotechnology fields of genetics and gene therapy, excluding production technologies; testing of pharmaceuticals in the field of genetics and gene therapy; laboratory research services relating to pharmaceuticals in the field of genetics and gene therapy; conducting early evaluations in the field of new pharmaceuticals in the field of genetics and gene therapy; providing medical and scientific research information in the field of pharmaceuticals and clinical trials in the field of genetics and gene therapy; medical research services in the field of genetics and gene therapy; medical research services in the field of genetic blood disorders; medical research services in the field of genetic ocular disorders; scientific research for medical purposes in the field of gene editing and genetic disorders; scientific research for medical purposes in the field of nuclease and nuclease panel discovery and optimization for the development of gene-targeting pharmaceuticals
Owner
- EmendoBio Inc., New York, NY, US
- EmendoBio Inc., New York, NY, US
Prosecution history
- 05 Nov 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 05 Nov 2025 — SOU EXTENSION 1 GRANTED
- 04 Nov 2025 — SOU EXTENSION 1 FILED
- 04 Nov 2025 — SOU TEAS EXTENSION RECEIVED
- 06 May 2025 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 24 Mar 2025 — TTAB RELEASE CASE TO TRADEMARKS
- 24 Mar 2025 — OPPOSITION TERMINATED NO. 999999
- 24 Mar 2025 — OPPOSITION DISMISSED NO. 999999
- 10 Mar 2025 — ASSIGNED TO EXAMINER
- 26 Jun 2023 — OPPOSITION INSTITUTED NO. 999999
- 24 Jan 2023 — EXTENSION OF TIME TO OPPOSE RECEIVED
- 27 Dec 2022 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 27 Dec 2022 — PUBLISHED FOR OPPOSITION
- 07 Dec 2022 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 22 Nov 2022 — APPROVED FOR PUB - PRINCIPAL REGISTER